Interest in Brucella species as a biological weapon stems from the fact that airborne transmission of the agent is possible. It is highly contagious and enters through mucous membranes such as the conjunctiva, oropharynx, respiratory tract and skin abrasions. It has been estimated that 10-100 organisms only are sufficient to constitute an infectious aerosol dose for humans. Signs and symptoms are similar in patients whatever the route of transmission and are mostly non-specific. Symptoms of patients infected by aerosol are indistinguishable from those of patients infected by other routes. Regimens containing doxycycline plus streptomycin or doxycycline plus rifampin are effective for most forms of brucellosis. Isolation of patients is not necessary.
Introduction
Brucellosis (also named Mediterranean fever, Gibraltar fever, Malta fever, Cyprus fever, undulant fever and typhomalarial fever) is a zoonotic infection caused by bacteria from the Brucella sp. Currently, of the six main biovars of Brucella, four are associated with moderate-to-significant human pathogenicity [1] . These biovars are found in goats and cattle (B. melitensis), swine (B. suis), cattle and bisons (B. abortus) and dogs (B. canis). B. melitensis occurs more frequently in humans than any of the other types and is the most virulent, pathogenic and invasive species, followed by B. suis, B. abortus and B. canis. There is an epidemiological link with consumption of raw milk from cattle infected with B. abortus and human cases of brucellosis [1] . Abortions are common in animals infected with any Brucella species, but not in similarly infected pregnant women [1, 2] . The infection occurs worldwide in both humans and animals, but is most common in the Mediterranean countries of Europe and Africa, the Middle East, India, Central Asia, Mexico, and Central and South America [2] . Transmission of brucellosis to humans is usually the result of ingestion, direct contact via cuts or abrasions of the skin, mucous membranes or inhalation [1, 2] . Risk factors for infection include handling of infected animals (tissues and body fluids such as blood, urine, vaginal discharges, aborted animal foetuses and especially placentae), ingestion of contaminated animal products such as meat, raw or unpasteurised milk and milk products [1] . Persons at high risk are those working (farmers, veterinarians, abattoir workers) with infected agricultural animals such as cattle, pigs, sheep, camels and goats. Brucella is one of the most common organisms acquired due to laboratory exposure usually by aerosolisation [3] . Airborne infection has also been reported in pens and stables of infected animals. Outbreaks of brucellosis are usually reported after inhalation of aerosols. Rare cases have occurred from accidental self-inoculation of the B. abortus vaccine strain 19 and the B. melitensis animal vaccine strain Rev-1 [4, 5] . Person-to-person transmission usually does not occur, with the exception of the very rare cases reported following blood exposure, primary exposure to infected tissues or after sexual contact.
Brucellosis and bioterrorism
Interest in Brucella species as a biological weapon stems from the fact that airborne transmission of the agent is possible (e.g. human airborne transmission during abortions of infected animals, aerosolisation in laboratories). It is highly contagious, as it can enter through mucous membranes such as the conjunctiva, oropharynx, respiratory tract and skin abrasions. It has been estimated that only 10-100 organisms are needed to constitute an infectious aerosol dose for humans [2] . Brucella is sensitive to exposure to heat and most disinfectants but can survive in the environment for up to two years under specific conditions, becoming a continuing threat to both humans and animals. In 1954, B. suis became the first agent weaponised by the United States (US). Several other countries have or are suspected to have weaponised this agent, including the United Kingdom (UK), although to our knowledge, this agent has never been used as a biological weapon [6] . Nevertheless, Brucella, particularly B. melitensis and B. suis, is considered one of the agents of lesser threat. The incubation period is rather long, many infections are asymptomatic and the mortality is low. However, the agent might be used more as an incapacitating agent, as the disease is associated with a high morbidity combining a protracted illness.
Microbiological characteristics
Brucella is a small, Gram negative aerobic coccobacillus that grows extra-and intracellularly within macrophages. It lacks capsule, flagellae, endospore or native plasmid. The genus Brucella contains six species with multiple biotypes that vary in terms of biochemical reactions, host specificity and pathogenicity for humans [1] . The species affecting humans are mentioned above, while B. ovis and B. neotomae are not infectious for humans. The principal virulence factor of Brucella is the cell-wall lipopolysaccharide. Strains with smooth lipopolysaccharide are more virulent and more resistant to intracellular destruction by polymorphonuclear leukocytes.
Clinical features
Signs and symptoms are similar in patients whatever the route of transmission and are mostly non-specific (TABLE I) . Symptoms of patients infected by aerosol are indistinguishable from those of patients infected by other routes [2] . Physical examination is usually without abnormalities A high degree of suspicion is imperative in order to establish the diagnosis. The incubation period of brucellosis is highly variable, from one to 60 days, up to several months, with an average of 1-2 months. The illness may be mild and self-limited or severe. Onset of the disease may be abrupt or insidious (50%). Brucellosis is a systemic infection that can involve any organ or organ system. It is generally characterised by fever, which may be continuous, intermittent or irregular [1] . Fever, which is the most common symptom (90%-95%), may be associated with other symptoms such as weakness, profuse sweating (40%-90%), chills, diffuse or localised arthralgias (20%-40%), malaise (80%-95%), weight loss and generalised pain (40%-70%) [2, [7] [8] [9] . Neuropsychiatric complaints, which include headache, depression and irritability, are frequent. Gastrointestinal symptoms such as anorexia, nausea, vomiting, abdominal pain, diarrhoea or constipation are also frequent (up to 70% of cases). Rare cases of ileitis, colitis or peritonitis have been reported with B. melitensis [1] . The liver is involved in the great majority of cases as shown by a mild increase of liver function enzymes.
Non-caseating epithelioid granulomas indistinguishable from the ones seen in sarcoidosis can be found in liver biopsy.
Hepatic abscesses and acute cholecystitis have also been reported. Cough and chest pain are present in 15%-25% of infected patients with a normal chest radiograph [1] . Lung abscesses, nodules and pleural effusions have been reported. Lymphadenopathies are present in 10%-20% of patients and 20%-70% experience splenomegaly and/or hepatomegaly (10%-30%). Cutaneous manifestations may include ulcerations, petechiae, purpura, and erythema nodosum. Osteoarticular complications of brucellosis are common (up to 40%) and include sacroileitis, which represents the most frequently involved joint, peripheral joint arthritis, bursitis, osteomyelitis and particularly vertebral osteomyelitis or spondylitis (6%) [1, 10, 11] . Arthritis of peripheral joints usually involves large joints such as the hips, knees and ankles. Osteoarticular complications are usually due to B. melitensis. Other complications such as epididymo-orchitis, meningitis (manifested by lymphocytic pleocytosis, elevated protein and normal-low glucose in the CSF), encephalitis, seizures and neuropathies are less frequent (<2%). Severe behavioural changes of unknown aetiology occur in some patients. Endocarditis occurs in approximately 2% of patients [1] . Other cardiovascular complications include myocarditis, pericarditis and aneurysms of the aorta and cerebral vessels [1] . In brucellosis, routine laboratory tests are commonly nonspecific: mild elevation of serum lactate dehydrogenase and alkaline phosphatase [2] . Haematological abnormalities may include anaemia, neutropenia and thrombocytopenia [12] . The case fatality rate is very low in untreated patients (less than 2%). It is usually due to B. melitensis endocarditis or meningitis. Nearly all patients respond to antibiotic treatment, with fewer than 10% manifesting relapses. The systemic symptoms may last for weeks or months. Most of the patients recover within a year, even without antibiotic treatment.
Diagnosis
The Tables 2 and 3 . It is definitively established by culture of the organism, which can be most frequently recovered from blood or bone marrow specimens. Positive culture may require 4 to 7 days to grow Brucella (up to 40 days). Blood cultures are positive in 10%-90% of patients and are not helpful for the initial diagnosis of the disease. More rapid detection of the organisms may be performed on BACTEC blood cultures [13] . Standard serological diagnosis using the tube agglutination test confirms the diagnosis when a single titre >160 is found or a four-fold rise in the antibody titre is noted between the onset of illness and convalescent-phase serum, collected 14-21 days after. ELISA and western blot are also available, but these methods lack standardisation. PCR may demonstrate the presence of the organism in some cases [2] .
Treatment
A six-week regimen containing doxycycline plus streptomycin or doxycycline plus rifampicin are effective for most forms of brucellosis [2, 14, 15] (TABLE IV) . Isolation of patients is not necessary. Patients with endocarditis, spondylitis or meningoencephalitis may need to be treated for longer. Endocarditis requires doxycycline plus streptomycin plus rifampicin and may nevertheless require valve replacement. Trimethoprim-sulfamethoxazole and fluoroquinolones also have good results against Brucella, but are associated with high relapse rates when used as monotherapy. The combination of ofloxacin plus rifampicin is associated with good results [15] . Even if there is little evidence to support its utility for postexposure prophylaxis, doxycycline plus rifampicin is recommended for 3 to 6 weeks [14,15]. There is currently no authorised human Brucella vaccine in the European Union or the US. There are some limited clinical data on a live, attenuated vaccine-candidate strain from the former Soviet Union and China. Due to the frequency of adverse events and the short duration of immunity, it seems that it is no longer used [16] . Sub-unit vaccine candidates have also been studied but evidence of efficacy is inconclusive. The potential to develop human Brucella vaccine is limited by the small market potential, which will probably restrict development efforts to national defence agencies only [16].
In conclusion, brucellosis has been reported as a possibility after a bioterrorist act. The agent is stable and could be transmitted by the airborne route. But the disease is associated with low mortality and has a comparatively limited impact. 
Management
• Antibiotics (see Table 4 ) and supportive care
• Spondylitis and endocarditis complications need long treatment courses and possibly surgical treatment • Post-exposure prophylaxis: doxycycline and rifampicin (see Table 4 ) • No approved human vaccine available 
First line treatment
-Doxycycline: 100 mg IV bid followed by 100 mg bid per os and -Rifampicin: 10-15 mg/kg/day in 1 or 2 doses, followed by 600-900 mg per os once daily or -Gentamicin: 3-5 mg/kg IV once daily or 1.5-2.5 mg/kg twice daily (max 2 weeks) or -Streptomycin: 1 g IM once or twice daily (max 2 weeks) -Doxycycline: 100 mg bid per os and -Rifampicin: 600-900 mg per os once daily Second line treatment or first line treatment as an alternative for pregnant women -Trimethoprim (6-8 mg/kg/day) + sulfamethoxazole (40 mg/kg/day) IV in 1 or 2 divided doses followed by Trimethoprim (6-8 mg/kg/day) + sulfamethoxazole (40 mg/kg/day) per os in 1 or 2 divided doses and -Rifampicin: 10-15 mg/kg/day in 1 or 2 doses, followed by 600-900 mg per os once daily -Not recommended
Children
First line treatment In children > 8 years -Doxycycline: . > 45 kg: idem adult . < 45 kg: 2.2 mg/kg IV twice daily followed by 2.2 mg/kg per os twice daily and -Rifampicin: 10-15 mg/kg/day in 1 or 2 doses, followed by 10-15 mg/kg per os in 1 or 2 doses daily or -Gentamicin: 1-2. 
